AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9647680 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in written verbal input format
Number of subjects: 1
Study 9647680 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in spoken verbal input format
Number of subjects: 1
Study 8568337 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood samples from patients with acute pancreatitis
Number of subjects: 0
Study 2254515 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment targeting child and parent behavior
Number of subjects: 162
Study 2254515 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment
Number of subjects: 162
Study 6929102 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline infused i.v. during the operation and daily for 4 days postoperatively
Number of subjects: 158
Study 6929102 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline infused i.v. during the operation, plus 200 mg instilled into the peritoneal cavity at the completion of the operation
Number of subjects: 158
Study 6929102 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 158
Study 31600489 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block Using the Anterior Technique
Number of subjects: 0
Study 31600489 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31274211 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg vitamin D3
Number of subjects: 90
Study 31274211 — intervention group
Group type: COMPARATOR
Intervention: 1 mL normal saline (placebo)
Number of subjects: 90
Study 28446628 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP or AGP
Number of subjects: 114
Study 28446628 — intervention group
Group type: COMPARATOR
Intervention: Normal CRP and AGP
Number of subjects: 114
Study 26070652 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose L-T4 treatment for 5 weeks (HD group)
Number of subjects: 55
Study 26070652 — intervention group
Group type: COMPARATOR
Intervention: Conventional L-T4 withdrawal (TW group)
Number of subjects: 55
Study 26070652 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose L-T4 treatment (HD group)
Number of subjects: 55
Study 25002722 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly topotecan 4 mg/m² IV with ziv-aflibercept 6 mg/kg IV every 21 days
Number of subjects: 189
Study 25002722 — intervention group
Group type: COMPARATOR
Intervention: Weekly topotecan 4 mg/m² IV
Number of subjects: 189
Study 25002722 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ziv-aflibercept and topotecan
Number of subjects: 189
Study 25002722 — intervention group
Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 189
Study 22332815 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biofeedback (BFB) combined with assisted low-intensity postoperative perineal physiokinesitherapy.
Number of subjects: 32
Study 22332815 — intervention group
Group type: COMPARATOR
Intervention: Control group received only oral and written instructions on Kegel exercises after catheter removal.
Number of subjects: 32
Study 19295468 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm/gel provision
Number of subjects: 2040
Study 19295468 — intervention group
Group type: COMPARATOR
Intervention: Baseline predictors
Number of subjects: 2040
Study 17713339 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually designed patient-centered preventive program including counseling, toothbrushes, fluoride toothpaste, fluoride and xylitol lozenges, and fluoride/chlorhexidine varnish applications.
Number of subjects: 497
Study 17713339 — intervention group
Group type: COMPARATOR
Intervention: Basic prevention offered as standard in public dental clinics.
Number of subjects: 497
Study 15099605 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 15099605 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 15099605 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 0
Study 15099605 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 11448848 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion (WI) for 3 hours in HF patients
Number of subjects: 9
Study 11448848 — intervention group
Group type: COMPARATOR
Intervention: Control (seated position)
Number of subjects: 9
Study 11448848 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion (WI) with sustained angiotensin-converting enzyme inhibitor therapy in HF patients
Number of subjects: 9
Study 11448848 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during WI
Number of subjects: 9
Study 9608577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine + Scopolamine
Number of subjects: 8
Study 9608577 — intervention group
Group type: COMPARATOR
Intervention: Mecamylamine
Number of subjects: 8
Study 9608577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 588
Study 7996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 588
Study 7996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 588
Study 7996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 588
Study 7996097 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus penicillin
Number of subjects: 588
Study 7996097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 1978478 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 434
Study 1978478 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 434
Study 375408 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole at 3 mg/kg daily for 8 days
Number of subjects: 0
Study 375408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole at 6 mg/kg daily for 10 days following 8 days of levamisole
Number of subjects: 0
Study 375408 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) at 6 mg/kg daily for 12 days
Number of subjects: 0
Study 375408 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 375408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 0
Study 31992320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk human health and medical research exempt from ethics reviews
Number of subjects: 0
Study 31992320 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing non-identifiable data and specimens
Number of subjects: 0
Study 31992320 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of public benefit or service programme
Number of subjects: 0
Study 31992320 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 31992320 — intervention group
Group type: COMPARATOR
Intervention: Research with staff in their professional role
Number of subjects: 0
Study 31992320 — intervention group
Group type: COMPARATOR
Intervention: Audit and service evaluation
Number of subjects: 0
Study 31992320 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining categories
Number of subjects: 0
Study 31380891 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3007
Study 31380891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 3007
Study 31380891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3007
Study 31380891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bleeding-risk procedure (Apixaban)
Number of subjects: 3007
Study 31380891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bleeding-risk procedure (Rivaroxaban)
Number of subjects: 3007
Study 28862466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth powder
Number of subjects: 154
Study 28862466 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste (Control)
Number of subjects: 154
Study 25647203 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 ratio (338 patients)
Number of subjects: 680
Study 25647203 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 ratio (342 patients)
Number of subjects: 680
Study 23613192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prineo™ (2-octyl cyanoacrylate with self-adhering mesh)
Number of subjects: 60
Study 23613192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prineo™
Number of subjects: 60
Study 22036100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 51
Study 22036100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 51
Study 23120599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty
Number of subjects: 50
Study 23120599 — intervention group
Group type: COMPARATOR
Intervention: Conventional septoplasty
Number of subjects: 50
Study 17109748 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 176
Study 17109748 — intervention group
Group type: COMPARATOR
Intervention: Splinting
Number of subjects: 176
Study 15011821 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 1522
Study 15011821 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed diagnosis repairs
Number of subjects: 1522
Study 15011821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary-enteric anastomosis
Number of subjects: 1522
Study 11176742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal BLB group (BLB > or =80 microg and <600 microg)
Number of subjects: 110
Study 11176742 — intervention group
Group type: COMPARATOR
Intervention: Low BLB group (BLB <80 microg)
Number of subjects: 110
Study 11176742 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy for patients with high-normal BLB
Number of subjects: 110
Study 9598258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40
Study 9598258 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study 7535192 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 0
Study 7535192 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs inhibiting nitric oxide (NO)
Number of subjects: 0
Study 3377974 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid crystals and 60% salicylic acid ointment
Number of subjects: 57
Study 3377974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30606082 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing xylitol-free gum for 30 minutes at 3, 5, and 7 hours postoperatively
Number of subjects: 150
Study 30606082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 150
Study 30998830 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurring presentation of harder or softer pairs
Number of subjects: 0
Study 30998830 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prior information (video of indentation)
Number of subjects: 0
Study 30998830 — intervention group
Group type: COMPARATOR
Intervention: Control condition (randomized presentation)
Number of subjects: 0
Study 30998830 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit prior information during blocked condition
Number of subjects: 0
Study 30998830 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit-only group (no explicit information)
Number of subjects: 0
Study 28059619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rotavirus vaccine (RV) before injection
Number of subjects: 352
Study 28059619 — intervention group
Group type: COMPARATOR
Intervention: Oral rotavirus vaccine (RV) after injection
Number of subjects: 352
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: DSA negative and DSA MFI <2000 (Group A, n = 316)
Number of subjects: 345
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ≤ MFI < 10,000 (Group B, n = 19)
Number of subjects: 345
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: MFI ≥ 10,000 (Group C, n = 10)
Number of subjects: 345
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAs (MFI ≥ 10,000)
Number of subjects: 345
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAs (MFI ≥ 2000)
Number of subjects: 345
Study 26156584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary graft failure (GF)
Number of subjects: 345
Study 23392717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 64
Study 23392717 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study 21730870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation (EPBD)
Number of subjects: 86
Study 21730870 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 86
Study 19549749 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 3524
Study 19549749 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc
Number of subjects: 3524
Study 19549749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement
Number of subjects: 3524
Study 19549749 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (control)
Number of subjects: 3524
Study 16819379 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + E (polyethylene glycol 3350 plus electrolytes)
Number of subjects: 63
Study 16819379 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 63
Study 15320956 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily
Number of subjects: 0
Study 15320956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram daily
Number of subjects: 0
Study 15320956 — intervention group
Group type: COMPARATOR
Intervention: 40 mg citalopram daily
Number of subjects: 0
Study 15320956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram after 8 weeks
Number of subjects: 0
Study 11055323 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-acetyl-7-oxo-DHEA (50 mg/d for 7 days, 100 mg/d for 7 days, 200 mg/d for 28 days)
Number of subjects: 22
Study 11055323 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-acetyl-7-oxo-DHEA (200 mg/d for 28 days)
Number of subjects: 22
Study 11055323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9463836 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sertraline
Number of subjects: 7
Study 9463836 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine
Number of subjects: 7
Study 9463836 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 7
Study 8302414 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA liquid (mean dose 312 mg/day)
Number of subjects: 20
Study 8302414 — intervention group
Group type: COMPARATOR
Intervention: CSA capsules (mean dose 312 mg/day)
Number of subjects: 20
Study 8302414 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA liquid
Number of subjects: 20
Study 8302414 — intervention group
Group type: COMPARATOR
Intervention: CSA capsules
Number of subjects: 20
Study 3532669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction alone
Number of subjects: 15
Study 3532669 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy with dietary advice
Number of subjects: 15
Study 3532669 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 15
Study 29734232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid (triamcinolone 20 mg)
Number of subjects: 28
Study 29734232 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study 27118785 — intervention group
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate 40 mg single administration (LO‐40SD)
Number of subjects: 803
Study 27118785 — intervention group
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate 20 mg once daily for 2 days (LO‐20TD)
Number of subjects: 803
Study 27118785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 24997349 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 31
Study 24997349 — intervention group
Group type: COMPARATOR
Intervention: Resting condition of silent reading
Number of subjects: 31
Study 22513048 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg/d; group O, n=10)
Number of subjects: 20
Study 22513048 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide (30 mg/d; group M, n=10)
Number of subjects: 20
Study 20381932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (8 sessions, 60 min each over 8 weeks)
Number of subjects: 40
Study 20381932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 18541546 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP-enriched whey protein isolate (GMP-WPI)
Number of subjects: 127
Study 18541546 — intervention group
Group type: COMPARATOR
Intervention: Skim milk powder (SMP)
Number of subjects: 127
Study 18541546 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP-WPI and SMP (both groups)
Number of subjects: 127
Study 15572587 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HiDAC) alone, 3 courses
Number of subjects: 474
Study 15572587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy regimen (1 course of HiDAC, 1 course with etoposide and cyclophosphamide, 1 course with diaziquone and mitoxantrone)
Number of subjects: 474
Study 15572587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (HiDAC and multiagent chemotherapy)
Number of subjects: 474
Study 12867227 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorder for 1 month
Number of subjects: 100
Study 12867227 — intervention group
Group type: COMPARATOR
Intervention: Holter monitor for 48 hours
Number of subjects: 100
Study 12867227 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorder after negative Holter monitoring
Number of subjects: 100
Study 12867227 — intervention group
Group type: COMPARATOR
Intervention: Holter monitor after negative loop recorder
Number of subjects: 100
Study 12867227 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorders overall
Number of subjects: 100
Study 12867227 — intervention group
Group type: COMPARATOR
Intervention: Holter monitors overall
Number of subjects: 100
Study 12867227 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorder activation
Number of subjects: 100
Study 10537442 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of lamivudine to zidovudine-containing regimens for 1 year
Number of subjects: 1840
Study 10537442 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of lamivudine to zidovudine-containing regimens
Number of subjects: 1840
Study 8867494 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT
Number of subjects: 30
Study 2072075 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental departments (prevention programme)
Number of subjects: 412
Study 2072075 — intervention group
Group type: COMPARATOR
Intervention: Control departments
Number of subjects: 412
Study 2072075 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental departments (women)
Number of subjects: 412
Study 2072075 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental departments (men)
Number of subjects: 412
Study 6439036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 22
Study 6439036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31301034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Resistance Training (BFR‐RT) at 30% 1RM
Number of subjects: 24
Study 31301034 — intervention group
Group type: COMPARATOR
Intervention: Traditional Heavy Load Resistance Training (HL‐RT) at 70% 1RM
Number of subjects: 24
Study 31301034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Resistance Training (BFR‐RT)
Number of subjects: 24
Study 31301034 — intervention group
Group type: COMPARATOR
Intervention: Traditional Heavy Load Resistance Training (HL‐RT)
Number of subjects: 24
Study 29032859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA tuna oil (800mg/day DHA)
Number of subjects: 252
Study 29032859 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 252
Study 26829088 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation during weight-bearing exercises
Number of subjects: 42
Study 26829088 — intervention group
Group type: COMPARATOR
Intervention: Control group (selected program without neuromuscular electrical stimulation)
Number of subjects: 42
Study 24850433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted chlorhexidine gluconate (0.4% to 100%)
Number of subjects: 60
Study 24850433 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study 24850433 — intervention group
Group type: EXPERIMENTAL
Intervention: Two scrubs of 50% diluted CHG
Number of subjects: 60
Study 24850433 — intervention group
Group type: EXPERIMENTAL
Intervention: One scrub of 50% diluted CHG
Number of subjects: 60
Study 22920577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment (intramuscularly)
Number of subjects: 75
Study 21060024 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by surgery
Number of subjects: 144
Study 21060024 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 144
Study 21060024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 17637792 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 129
Study 17637792 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 129
Study 17637792 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched hypertensive subjects without LV hypertrophy)
Number of subjects: 129
Study 16182827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (initial oral dose 0.2 mg/kg) with MMF (2 to 3 g per day) and rATG induction therapy (4 mg/kg for 4 days)
Number of subjects: 103